New Announcement
NEW!Click here for a free, online course on various data extraction tools, with a focus on SRDR+.The course is offered through the Evidence Synthesis Academy.
SRDR+:
Moving systematic reviews forward.
SRDR+ is a free, powerful, easy to use tool for data extraction, management, and archival during systematic reviews.
Already have an account?
Get started now.

See how you can work with SRDR+

Researchers

Use SRDR+ as a free platform for extracting, archiving, and sharing data during systematic reviews and accessing shared data related to systematic reviews.

Guideline Developers

Use SRDR+ for accessing data related to systematic reviews when producing guidelines and recommendation statements for their constituencies.

Educators & Librarians

Use SRDR+ for instructing students and trainees in the best practices related to research methodology and evaluation.

Clinicians

Use SRDR+ for quick reference to study data that are relevant to clinical questions based on systematic reviews.

Policymakers

Use SRDR+ for quick reference to study data that are relevant to policy questions or recommendations based on systematic reviews.

Leading professionals love SRDR+

Image of Matthias Perleth

Mathias Perleth, MPH

Board Treasurer, International Network of Agencies for Health Technology Assessment [INAHTA], Germany
“In my regard, SRDR is among the most relevant developments in recent years!”
Image of Christine Clifford

Christine Clifford, MHP

Project Director, Eunice Kennedy Shriver Center, University of Massachusetts Medical School, USA
“I like SRDR’s use of the Tabs and the separation by topic area of the Tabs; it allows for focus on sections of a paper at a time. SRDR is powerful and adaptable, provides a way to standardize diverse results, and provides structure.“
Image of Tianjing Li

Tianjing Li, MD, MHS, PhD

Director, Cochrane Eyes and Vision United States Satellite, Associate Professor, Johns Hopkins Bloomberg School of Public Health, USA
“SRDR is one of the few data systems designed specifically for producing and archiving systematic reviews with the intention to share the data with the public. It’s extremely flexible and it allows users to design their forms (and data items on the forms) in a way that best suit their needs and workflow.”
Image of James Scott Parrott

James Scott Parrott, PhD

Professor, Rutgers University School of Health Professions, USA
“The structure of SRDR lends itself well to teaching metacognitive processes associated with linking the discrete steps of the evidence analysis process. Another benefit is the flexibility of SRDR to handle diagnostic accuracy as well as etiology, treatment, and prognosis questions during systematic reviews.”

Create your systematic review project today

SRDR+ has a variety of features that make it the best place to conduct systematic reviews.
Build electronic data extraction forms
Extract and compare data
Collaborate with your team
Customize exports of your datasets

Access study data from published systematic reviews today.

Browse topics with available study data.
Download study data
Use study data in your own systematic review.

Recently published projects

First published on February 02, 2021
Last edited on February 19, 2021
Automated-Entry Patient Generated Health Data for Chronic Conditions: The Evidence on Health Outcomes
128 Studies • 50 Key Questions • 10 Extraction Forms
Objectives: Technical brief for AHRQ on the evidence for whether PGHD devices and apps improve health outcomes for chronic conditions
First published on July 05, 2020
Last edited on February 14, 2021
The effect of IDH inhibitors in AML patients.
4 Studies • 2 Key Questions • 1 Extraction Forms
Objectives: 12% of patients with AML harbor mutation at Isocitrate dehydrogenase enzyme (IDH).Mutations at these enzymes result in high level of R2 hydroxyglutarate which competes with 2-alpha-hydroxygluterate resulted in DNA and histone hypermethylation. DNA and histone hypermethylation inhibits cell differentiation and promotes leukemic transformation. Ivosidenib and Enasidenib are IDH inhibitors that promotes cell differentiation and showed promising activity in phase1 and 2 trials in relapse/refractory AML patients and in elderly patients who are not candidate for traditional induction regimens. In this systematic review and meta-analysis, we intend to integrate the results of phase1 and 2 trials that looked at the efficacy and the side effects of IDH inhibitor. Therefore,we will have a clearer picture regarding the efficacy and side effect of these medications.
First published on February 12, 2019
Last edited on February 19, 2021
SRDR Project Indexing
183 Studies • 1 Key Questions • 1 Extraction Forms
Objectives: This is a Methods Research project that catalogs the various projects with publicly available data on the SRDR Webpage.

Join thousands of professionals